GlassScriptPhysician profile
Kathryn M Schoch
NPI 1124262753
$11,157.41
in general payments reported to CMS, 2019-2025
23 companies · $3,567 in 2025
The $3,567 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $1,469 · 2023: $2,034 · 2024: $3,477 · 2025: $3,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,672 · Education: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,671.61 |
| Education | $406.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,016.21 | 2021-2025 | |
| Janssen Biotech, INC. | $1,285.08 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $993.82 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $957.16 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $862.51 | 2022-2025 | Sotyktu |
| Amgen INC. | $850.03 | 2022-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $799.75 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Leo Pharma INC. | $627.29 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $508.42 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $455.89 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $407.87 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $254.27 | 2021-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $240.59 | 2024-2025 | Dupixent, Libtayo |
| Pfizer INC. | $224.92 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $172.41 | 2023-2025 | Idacio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $133.41 | 2023-2025 | Nexplanon, Vtama, Hadlima |
| Genzyme Corporation | $95.89 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.71 | 2023-2024 | Spevigo |
| Dermavant Sciences, INC. | $73.38 | 2023-2024 | Vtama |
| Botanix Sb INC | $38.27 | 2025 | Sofdra |
| Sandoz INC. | $26.74 | 2024 | |
| Biofrontera INC. | $22.85 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Astrazeneca Pharmaceuticals LP | $15.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Schoch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.